BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer

NCT02379247 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: BYL-719 (alpelisib)
DRUG: Nab-paclitaxel

Sponsor

Priyanka Sharma

Collaborators

[object Object]